HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway

Cancer Gene Therapy

Volumn 19, Issue 9, 2012, Pages 601-608

  Yao, Y ^a   Fang, Z P ^b   Chen, H ^a   Yue, L ^c   Min, D L ^a   Tang, L N ^a   Yu, W X ^a   Kung, H F ^d   Lin, M C ^d   Shen, Z ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^c QINGDAO UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AAV HGFK1; bone metastasis; breast cancer; TAK1 p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA ACTIN; ENHANCED GREEN FLUORESCENT PROTEIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARVOVIRUS VECTOR; PROTEIN HGFK1; PROTEIN MAPKAPK2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER INVASION; CANCER MODEL; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DEPENDOVIRUS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KRINGLES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84865204287     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.38     Document Type: Article

References (22)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
2. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169-180.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
4. Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704: 49-57.
5. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006; 3: 41-49.
6. Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther 2007; 7: 221-232.
7. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25: 541-549.
8. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-696.
9. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
10. Xin L, Xu R, Zhang Q, Li TP, Gan RB. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun 2000; 277: 186-190.
11. Shen Z, Yang ZF, Gao Y, Li JC, Chen HX, Liu CC et al. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 2008; 68: 404-414.
12. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007; 282: 26656-26664.
13. Chen Y, Luk KD, Cheung KM, Xu R, Lin MC, Lu WW et al. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Therapy 2003; 10: 1345-1353.
14. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12: 5369-5376.
15. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-1287.
16. Singh AS, Figg WD. In vivo models of prostate cancer metastasis to bone. J Urol 2005; 174: 820-826.
17. Ponnazhagan S, Mahendra G, Kumar S, Shaw DR, Stockard CR, Grizzle WE et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: longterm efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004; 64: 1781-1787.
18. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 2006; 66: 4319-4328.
19. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010; 29: 6485-6498.
20. Yu L, Hebert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 2002; 21: 3749-3759.
21. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol 2008; 28: 322-328.
22. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011; 6: e19234.